GlaxoSmithKline
This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced solid cancers. The study aims to determine: * What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? * How does the body handle the drug(s)? * What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply: * Male or female participants at least 18 years of age (≥18 years) at the time of signing the informed consent form (ICF). * Participants with histologically confirmed advanced/metastatic solid tumors, irrespective of mutational status, as defined per cohort, as follows: ES-SCLC * Histologically or cytologically confirmed SCLC (prior pathological diagnosis of complex SCLC \[such as mixed SCLC and NSCLC\] or transformed SCLC \[NSCLC to SCLC\] is not allowed) * ES-SCLC \[per Ve…
Risvutatug rezetecan will be administered
Ivonescimab will be administered
Arctuva estimate
Verify or correct the compensation shown for this listing.